# A Clinical Pharmacology Study of K-877 Controlled Release Tablet

> **NCT04079530** · PHASE2 · COMPLETED · sponsor: **Kowa Company, Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** K-877 IR 0.2 mg/day
- **DRUG:** K-877 CR 0.4 mg/day
- **DRUG:** K-877 CR 0.8 mg/day

## Key facts

- **NCT ID:** NCT04079530
- **Lead sponsor:** Kowa Company, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-13
- **Primary completion:** 2019-12-24
- **Final completion:** 2019-12-24
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04079530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04079530, "A Clinical Pharmacology Study of K-877 Controlled Release Tablet". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04079530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*